Click Here

ABBREVIATIONS

DS: Dravet syndrome; LGS: Lennox-Gastaut syndrome; TSC: tuberous sclerosis complex.

* Clobazam currently does not have marketing authorisation in Norway.

† EPIDYOLEX® demonstrated clinically significant reductions in seizure frequency in LGS, DS & TSC-associated seizures vs. placebo in clinical trials, as well as reduction in seizure severity from baseline.1,8

‡ Non–seizure-related outcomes were evaluated using the BECOME global survey.7

§ The most common adverse events associated with EPIDYOLEX® are decreased appetite, somnolence, vomiting, pyrexia, diarrhoea & fatigue. For more detailed safety information, please refer to the Summary of Product Characteristics.3

  1. Epidyolex® Summary of Product Characteristics. Approved: May 2023.
  2. Raga S, et al. Epileptic Disord. 2021;23(1):40–52.
  3. Marchese F, et al. SN Compr Clin Med. 2021;3:2167–2179.
  4. Patel AD, et al. Epilepsia. 2021;62(9):2228–2239.
  5. Scheffer IE, et al. Epilepsia. 2021;62(10):2505–2517.
  6. Thiele EA, et al. Epilepsia. 2022;63(2):426–439.
  7. Berg A, et al. Epilepsy Research. 2023;107280: 0920-1211.
  8. Privitera M, et al. Epilepsia. 2021;62:1130–1140.
  9. Cohen JM, et al. Epilepsia. 2021;62:2218–2227.
  10. Thiele EA, et al. Epilepsia. 2022;63(2):426–439.
  11. Billakota S, et al. Curr Opin Neurol. 2019;32:220–226.

REFERENCES

  1. Epidyolex® Summary of Product Characteristics. Approved: May 2023.
  2. Raga S, et al. Epileptic Disord. 2021;23(1):40–52.
  3. Marchese F, et al. SN Compr Clin Med. 2021;3:2167–2179.
  4. Patel AD, et al. Epilepsia. 2021;62(9):2228–2239.
  5. Scheffer IE, et al. Epilepsia. 2021;62(10):2505–2517.
  6. Thiele EA, et al. Epilepsia. 2022;63(2):426–439.
  7. Berg A, et al. Epilepsy Research. 2023;107280: 0920-1211.
  8. Privitera M, et al. Epilepsia. 2021;62:1130–1140.
  9. Cohen JM, et al. Epilepsia. 2021;62:2218–2227.
  10. Thiele EA, et al. Epilepsia. 2022;63(2):426–439.
  11. Billakota S, et al. Curr Opin Neurol. 2019;32:220–226.

ABBREVIATIONS

DS: Dravet syndrome; LGS: Lennox-Gastaut syndrome; TSC: tuberous sclerosis complex.

FOOTNOTES

* Clobazam currently does not have marketing authorisation in Norway.

† EPIDYOLEX® demonstrated clinically significant reductions in seizure frequency in LGS, DS & TSC-associated seizures vs. placebo in clinical trials, as well as reduction in seizure severity from baseline.1,8

‡ Non–seizure-related outcomes were evaluated using the BECOME global survey.7

§ The most common adverse events associated with EPIDYOLEX® are decreased appetite, somnolence, vomiting, pyrexia, diarrhoea & fatigue. For more detailed safety information, please refer to the Summary of Product Characteristics.3